KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Capital Expenditures (2016 - 2025)

Abbott Laboratories' Capital Expenditures history spans 17 years, with the latest figure at $689.0 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 4.31% year-over-year to $689.0 million; the TTM value through Dec 2025 reached $2.2 billion, down 1.63%, while the annual FY2025 figure was $2.2 billion, 1.63% down from the prior year.
  • Capital Expenditures for Q4 2025 was $689.0 million at Abbott Laboratories, up from $496.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $755.0 million in Q4 2023 and bottomed at $321.0 million in Q1 2022.
  • The 5-year median for Capital Expenditures is $499.0 million (2025), against an average of $512.1 million.
  • The largest annual shift saw Capital Expenditures crashed 35.67% in 2021 before it soared 33.77% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $614.0 million in 2021, then dropped by 0.65% to $610.0 million in 2022, then grew by 23.77% to $755.0 million in 2023, then dropped by 4.64% to $720.0 million in 2024, then dropped by 4.31% to $689.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Capital Expenditures are $689.0 million (Q4 2025), $496.0 million (Q3 2025), and $502.0 million (Q2 2025).